17-42329642-C-T
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM2PM5PP2PP3_StrongPP5_Very_Strong
The ENST00000264657.10(STAT3):c.1145G>A(p.Arg382Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R382L) has been classified as Pathogenic.
Frequency
Consequence
ENST00000264657.10 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
STAT3 | NM_139276.3 | c.1145G>A | p.Arg382Gln | missense_variant | 13/24 | ENST00000264657.10 | NP_644805.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
STAT3 | ENST00000264657.10 | c.1145G>A | p.Arg382Gln | missense_variant | 13/24 | 1 | NM_139276.3 | ENSP00000264657 | A1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 35
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hyper-IgE recurrent infection syndrome 1, autosomal dominant Pathogenic:4Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 09, 2023 | Variant summary: STAT3 c.1145G>A (p.Arg382Gln) results in a conservative amino acid change located in the STAT transcription factor, DNA-binding (IPR013801) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251470 control chromosomes. c.1145G>A has been reported in the literature in multiple individuals affected with Hyper IgE Syndrome (e.g. Holland 2007). It has been observed as de novo and also seen to segregate with disease. These data indicate that the variant is very likely to be associated with disease. Additionally, other variants affected the same codon have been associated with Hyper-IgE syndrome in HGMD and ClinVar (e.g. R382G, R382P and R382W). At least one publication reports experimental evidence evaluating an impact on protein function by severely reducing the DNA binding ability of the homodimer (He_2012). The following publications have been ascertained in the context of this evaluation (PMID: 17881745, 20159255, 22581330).Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Oct 19, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | This variant has been observed to be de novo in individuals affected with hyper-IgE syndrome (Holland SM, 2007). It also segregates with hyper-IgE syndrome in a family and has been identified in several individuals affected with hyper-IgE syndrome (Minegishi Y, 2007) and an individual with selective IgG subclass deficiency (Ohnishi H, 2016). This variant has been reported to affect STAT3 protein function (Minegishi Y, 2007). This sequence change replaces arginine with glutamine at codon 382 of the STAT3 protein (p.Arg382Gln). Other variant(s) that disrupt p.Arg382 residue have been determined to be pathogenic (Renner ED, 2007). The variant has been reported to the ClinVar database as Pathogenic. The p.Arg382Gln variant is novel (not in any individuals) in gnomAD Exomes and 1000 Genomes. The variant is predicted to be damaging by both SIFT and PolyPhen2. The amino acid change p.Arg382Gln in STAT3 is predicted as conserved by GERP++ and PhyloP across 100 vertebratesFor these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 18, 2007 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 15, 2021 | Published functional studies demonstrate markedly enhanced STAT3 AGG-element binding, increased AGG-promoter activation activity, impaired Th17 response, and reduced IgG levels resulting in increased susceptibility to recurrent infections (Minegishi et al., 2007; Xu et al., 2015; Moffitt et al., 2018); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 18591410, 27474157, 29368105, 29402895, 20859667, 21288777, 21792878, 22500887, 22581330, 23830147, 20093388, 26384563, 25686613, 26280891, 17676033, 24452316, 17881745, 27302695, 28197791, 30410549, 31596517, 32912316, 32499645, 32581362, 33225392, 32888943, 33717144, 18602572, 29463618) - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | May 01, 2022 | STAT3: PM1, PM2, PS3:Moderate, PS4:Moderate, PP2, PP3, PP4 - |
Hyper-IgE recurrent infection syndrome 1, autosomal dominant;C4288261:STAT3 gain of function Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2024 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 382 of the STAT3 protein (p.Arg382Gln). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with hyper-IgE syndrome (PMID: 17676033, 17881745, 20301786, 24452316, 27302695). In at least one individual the variant was observed to be de novo. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 18305). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt STAT3 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects STAT3 function (PMID: 17676033, 26384563). This variant disrupts the p.Arg382 amino acid residue in STAT3. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 17676033, 17881745, 17942886, 22581330). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Inherited Immunodeficiency Diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | research | NIHR Bioresource Rare Diseases, University of Cambridge | Jan 01, 2019 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at